Clinical study of pazufloxacin mesilate, a new quinolone antibacterial agent, in burn infections and tissue concentrations.
|
Accession number;00A0674200
|
| Title;Clinical study of pazufloxacin mesilate, a new quinolone antibacterial agent, in burn infections and tissue concentrations. |
| Author;
SUGIHARA TSUNEKI
(Hokkaido Univ., Sch. of Med.)
YOSHIDA TETSUNORI
(Sapporo City Hosp.)
MINAGAWA HIDEHIKO
(Hokkaido Univ., Sch. of Med.)
HONDA KOICHI
(Keisei Geka Memoriaru Byoin)
TAKEUCHI AKITERU
(Sapporo City Hosp.)
HONMA KEN'ICHI
(Obihiro Kosei Hosp.)
MAEDA KAZUHIKO
(Obihiro Kosei Hosp.)
KIMURA CHU
(Hakodate Chuo Byoin)
TSUTSUMIDA ARATA
(Teine Keijinkai Byoin)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.48;NO.6;PAGE.401-416(2000)
|
| Figure&Table&Reference;TBL.17, REF.15 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;To evaluate the efficacy, safety, and utility of pazufloxacin mesilate (PZFX, injectable), an injectable new quinolone antibiotic, a phase III clinical study was conducted in patients with burn infections at the Department of Plastic Surgery, Faculty of Medicine, Hokkaido University, and affiliated hospitals (a total of six institutions). Of the total of 10 patients treated with PZFX, one patient was excluded because of violation of the inclusion criteria. Thus, 9 patients were included in the analysis of clinical results and the findings are described below. PZFX was administered in a dose of 300mg twice a day in 1 case and 500mg twice a day in 8 cases. 1) The clinical results were rated excellent in 5 cases, good in 3 cases, and fair in 1 case, with an efficacy rate including good or better results of 8/9. When classified by daily dose, the efficacy rate was 1/1 for the dosage of 300mg twice a day and 7/8 for 500mg twice daily. 2) Evaluation of bacteriological efficacy showed an elimination rate of 0/1 for gram-positive organisms and 1/4 for gram-negative organisms in single infections, and 1/1 in polybacterial infections. The overall elimination rate was 2/6. One strain each of Enterococcus faecalis, Enterobacter cloacae, and Acinetobacter calcoaceticus disappeared, and one strain of Staphylococcus aureus (MSSA) and 3 strains of Pseudomonas aeruginosa persisted. 3) No adverse effects occurred in any of the 9 cases included in the analysis. Abnormal laboratory values were observed in 2 of the 9 cases included in the analysis. ALT and Al-P elevations were seen in 1 case and abnormal in urinary protein in 1 case. PZFX levels in dermal tissue in burns were determined in the Department of Plastic Surgery, Faculty of Medicine, Hokkaido University and affiliated hospitals (a total of 4 institutions), and the results below were obtained.... (author abst.) |
|
|
|
Related Articles;
|
|
